368 related articles for article (PubMed ID: 24407560)
1. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 Feb; 74(2):223-42. PubMed ID: 24407560
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Dhillon S
Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
Chwieduk CM
Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Zerilli T; Pyon EY
Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
[TBL] [Abstract][Full Text] [Related]
8. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Karasik A; Aschner P; Katzeff H; Davies MJ; Stein PP
Curr Med Res Opin; 2008 Feb; 24(2):489-96. PubMed ID: 18182122
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin.
Lyseng-Williamson KA
Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
[TBL] [Abstract][Full Text] [Related]
11. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
Prescrire Int; 2008 Feb; 17(93):12-5. PubMed ID: 18354861
[TBL] [Abstract][Full Text] [Related]
14. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
16. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Green J; Feinglos M
Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Deacon CF
Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
20. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
